started · updated
National Institute of Oncology develops TIL cancer therapy in Poland
The National Institute of Oncology in Warsaw is developing an innovative Tumor Infiltrating Lymphocyte (TIL) therapy. This method utilizes a patient’s own T-lymphocytes, which are isolated from tumor samples, multiplied in a laboratory, and then reintroduced to the patient to effectively destroy cancer cells.
Researchers have received a grant to develop this method specifically for ovarian cancer patients. Future plans include applying the therapy to melanoma and other skin cancers. The institute is also preparing to advance CAR-T cell therapies and research into antibody-drug conjugates (ADC) to address difficult-to-treat malignancies.
Entities
National Institute of Oncology · Piotr Rutkowski · Poland · Warsaw